NEW YORK (GenomeWeb News) — Molecular Diagnostics company SensiGen has received a $300,000 investment from Delaware Crossing Investor Group, a mid-Atlantic-based group of angel investors.
SensiGen, based in Ann Arbor, Mich., said it plans to use the funds to develop and sell its AttoSense molecular diagnostic technology, which blends PCR and mass spectrometry to locate biomarkers.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.